MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Precipio Operating Income 2011-2026 | PRPO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Precipio
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.62 M | -12.8 M | -9.61 M | -9.15 M | -11 M | -13.9 M | -15.5 M | -1.71 M | -8.92 M | -10.6 M | -15.8 M | -9.5 M | -2.97 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.71 M | -15.8 M | -9.93 M |
Quarterly Operating Income Precipio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -61 K | -824 K | -859 K | - | -597 K | -1.21 M | -2.07 M | - | -1.45 M | -2.29 M | -3.03 M | - | -3.23 M | -2.43 M | -4.81 M | - | -2.44 M | -2.13 M | -2.14 M | - | -2.43 M | -2.26 M | -2.2 M | - | -2.36 M | -2.3 M | -2.06 M | - | -4.12 M | -2.18 M | -2.45 M | - | -3.63 M | -801 K | -596 K | - | -363 K | -285 K | -2.24 M | - | -2.26 M | -2.4 M | -1.97 M | - | -3.99 M | -3.96 M | -3.54 M | - | -5.41 M | -2.92 M | -3.82 M | - | -2.43 M | -1.37 M | -2.44 M | - | -439 K | -1.62 M | -750 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -61 K | -5.41 M | -2.2 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 3.01 | -2.9 % | $ 97.7 K |  USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 38.55 | -1.56 % | $ 1.07 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 23.6 | -1.87 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 33.99 | 1.34 % | $ 366 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-876 M | $ 102.46 | 0.15 % | $ 19 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 26.04 | -0.78 % | $ 787 M | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.43 | -3.06 % | $ 1.82 M | USA |
 |
Guardant Health
GH
|
-444 M | $ 111.67 | 1.08 % | $ 13.7 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
4.86 B | $ 219.24 | -0.1 % | $ 160 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Lantheus Holdings
LNTH
|
457 M | $ 65.81 | -1.3 % | $ 4.55 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
DexCom
DXCM
|
598 M | $ 73.07 | -1.26 % | $ 28.2 B | USA |
 |
CareDx, Inc
CDNA
|
-203 M | $ 20.32 | -2.31 % | $ 1.09 B | USA |
 |
NeoGenomics
NEO
|
-92.1 M | $ 11.84 | -4.52 % | $ 1.5 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 109.58 | -2.27 % | $ 4.32 B | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 11.0 | 6.8 % | $ 312 M | Israel |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 9.31 | -6.62 % | $ 552 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 145.86 | -2.56 % | $ 23.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
IQVIA Holdings
IQV
|
2.2 B | $ 229.99 | -2.33 % | $ 41.7 B | USA |
 |
Charles River Laboratories International
CRL
|
227 M | $ 210.32 | -0.64 % | $ 10.8 B | USA |
 |
Thermo Fisher Scientific
TMO
|
7.34 B | $ 581.3 | -1.83 % | $ 222 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.62 M | $ 0.84 | -5.23 % | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 39.99 | -3.82 % | $ 2.39 B | USA |
 |
Medpace Holdings
MEDP
|
447 M | $ 582.34 | -1.81 % | $ 18 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 184.75 | 1.32 % | $ 20.5 B | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 8.9 | -7.92 % | $ 1.15 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
1.09 B | $ 269.85 | 0.01 % | $ 22.6 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 178.39 | -4.03 % | $ 14.7 B | Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.13 B | $ 673.89 | -0.42 % | $ 55.6 B | USA |